KaloCyte
Baltimore, US · Founded 2016 · Missouri corporation · 23 employees on LinkedIn · 6 known investors
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply. The pre-clinical stage biotech company is supported by federal grants and investor funding.
Founders & leadership
KaloCyte was founded in 2016 by Allan Doctor, Dipanjan Pan, and Philip Spinella.
Investors · 6
Reported raises · per SEC filings
Form D private placements$800K disclosed across 1 round · 2018
▶$800KraisedMay 2018 · 3 investors · BiotechnologyRule 506(b)
▶$800KraisedMay 2018 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dipanjan PanDirector
- Daniel GetmanDirector
- Allan DoctorExecutive Officer, Director
- Gregory LanzaDirector
- Philip SpinellaDirector
- Offering amount
- $800K
- Amount sold
- $800K
- Minimum investment
- $10K
- First sale
- Apr 2018
- Incorporated
- Corporation, Missouri, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Medscape11 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
University of British Columbia11 shared keywordsThe University of British Columbia is a public university offering academic programs, research, and campus events across areas such as environmental science, business, music, and agriculture. It serves students, faculty, staff, and the public in British Columbia, Canada.
Companies competing with KaloCyte for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does KaloCyte do?
- KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply. The pre-clinical stage biotech company is supported by federal grants and investor funding.
- Who founded KaloCyte?
- KaloCyte was founded by Allan Doctor, Dipanjan Pan, Philip Spinella in 2016.
- Who are KaloCyte's investors?
- KaloCyte's investors include BioAdvance, BioGenerator Ventures, Maryland TEDCO, NYBC Ventures, Old Line Capital Partners, TEDCO.
- How much funding has KaloCyte raised?
- KaloCyte has disclosed $800K raised across 1 round.
- Where is KaloCyte headquartered?
- KaloCyte is headquartered in Baltimore, US.